A novel tetraaza macrocyclic Schiff base ligand and its metal complexes [Zn(II), Cu(II), and Co(II)] were successfully synthesized and characterized using various analytical techniques including FT-IR, NMR, ESI-MS, UV-Vis, PXRD, ESR, and TGA. The chemical reactivity and molecular geometry of the compounds were further elucidated through DFT calculations. The synthesized compounds were evaluated for their anti-bacterial activity against both Gram +ve and Gram -ve bacteria. Remarkably, the metal complexes exhibited enhanced anti-bacterial activity compared to the ligand. All compounds displayed moderate antibacterial activity against various strains, with complexes 4a and 4b demonstrating the highest inhibition against Gram +ve bacteria at 0.1 µM concentration. Furthermore, the cytotoxicity of these compounds against a human liver cancer cell line (HepG2) was assessed, revealing substantial anti-proliferative activity. Notably, the Zn(II) complex demonstrated an IC50 value comparable to the standard drug Doxorubicin. Importantly, the ligand and Zn(II) and Co(II) complexes exhibited minimal (< 5%) hemolysis at their IC50 values, suggesting their non-toxic nature. Molecular docking studies were conducted to investigate the binding interactions of the synthesized compounds with the active site of the topoisomerase IIβ enzyme (PDB ID: 4G0V), a crucial target for anti-bacterial and anti-cancer medications. Complex 4a displayed the strongest binding affinity (-8.2 kcal/mol) and the most favourable docked conformation, with multiple hydrogen bonds to the protein's active site. These results suggest its potential for further development as a therapeutic agent.
Read full abstract